Atrion Co. (ATRI) To Go Ex-Dividend on June 14th

Atrion Co. (NASDAQ:ATRI – Get Rating) declared a quarterly dividend on Tuesday, May 23rd, Zacks reports. Investors of record on Thursday, June 15th will be given a dividend of 2.15 per share by the medical instruments supplier on Friday, June 30th. This represents a $8.60 annualized dividend and a dividend yield of 1.55%. The ex-dividend date of this dividend is Wednesday, June 14th.

Atrion has increased its dividend payment by an average of 12.2% annually over the last three years and has raised its dividend annually for the last 19 consecutive years.

Atrion Price Performance

ATRI opened at $556.38 on Thursday. The firm has a fifty day moving average price of $610.63 and a 200 day moving average price of $619.00. Atrion has a 1 year low of $534.99 and a 1 year high of $705.74. The stock has a market cap of $979.23 million, a P/E ratio of 33.08 and a beta of 0.47.

Atrion (NASDAQ:ATRI – Get Rating) last posted its earnings results on Monday, February 27th. The medical instruments supplier reported $4.70 earnings per share (EPS) for the quarter. Atrion had a net margin of 17.01% and a return on equity of 12.36%. The firm had revenue of $42.86 million during the quarter.

Institutional Investors Weigh In On Atrion

A number of large investors have recently modified their holdings of the business. Goldman Sachs Group Inc. grew its holdings in shares of Atrion by 0.8% during the second quarter. Goldman Sachs Group Inc. now owns 1,929 shares of the medical instruments supplier’s stock worth $1,213,000 after buying an additional 16 shares in the last quarter. FMR LLC grew its holdings in shares of Atrion by 38.0% in the first quarter. FMR LLC now owns 69 shares of the medical instruments supplier’s stock valued at $43,000 after purchasing an additional 19 shares during the period. Pathstone Family Office LLC grew its holdings in shares of Atrion by 2.2% in the fourth quarter. Pathstone Family Office LLC now owns 920 shares of the medical instruments supplier’s stock valued at $517,000 after purchasing an additional 20 shares during the period. Royal Bank of Canada grew its holdings in shares of Atrion by 44.1% in the third quarter. Royal Bank of Canada now owns 134 shares of the medical instruments supplier’s stock valued at $76,000 after purchasing an additional 41 shares during the period. Finally, Citigroup Inc. grew its holdings in shares of Atrion by 63.1% in the first quarter. Citigroup Inc. now owns 106 shares of the medical instruments supplier’s stock valued at $67,000 after purchasing an additional 41 shares during the period. Hedge funds and other institutional investors own 64.90% of the company’s stock.

Analyst Upgrades and Downgrades

ATRI has been the subject of a number of research analyst reports. StockNews.com initiated coverage on shares of Atrion in a research report on Thursday, May 18th. They set a “hold” rating for the company. TheStreet cut shares of Atrion from a “b-” rating to a “c” rating in a research report on Monday.

About Atrion

(Get Rating)

Atrion Corp. engages in the manufacture and development of products for medical applications. It offers products for cardiovascular, fluid delivery, and ophthalmic. It also offers contract manufacturing and kitting services, and marine & aviation inflation components. The company was founded in 1944 and is headquartered in Allen, TX.